Literature DB >> 9462272

Expression of tenascin in lymphocytic autoimmune thyroiditis.

W Back1, C Heubner, J Winter, U Bleyl.   

Abstract

AIMS: To study the distribution of tenascin by immunocytochemistry in autoimmune diseases of the thyroid.
METHODS: Thyroids from patients with inflammatory lesions of the thyroid (lymphocytic thyroiditis Hashimoto, Grave's disease, thyroiditis DeQuervain) were studied by immunocytochemistry using antibodies against tenascin, collagen III, and collagen IV.
RESULTS: In autoimmune lymphocytic thyroiditis Hashimoto there was a characteristic corona-like staining pattern of tenascin around all activated lymph follicles with germinal centres. This staining pattern contrasted with the immunoreactions for collagen III and IV, which were not enhanced in the perilymphofollicular interstitium. In cases of thyroiditis DeQuervain the areas of early and ongoing fibrosis showed some diffuse staining for tenascin and for collagen III. Enhanced diffuse immunostaining for collagen IV in the perivascular and interfollicular interstitium was present in cases of Grave's disease. In Grave's disease no characteristic immunoreaction was detectable for tenascin.
CONCLUSIONS: The corona-like expression of tenascin around lymphofollicular infiltrates is distinctive of cases of lymphocytic thyroiditis. A similar staining pattern for tenascin has been reported in lymphoid hyperplasia of the thymus associated with myasthenia gravis, another autoimmunological disorder. There are good arguments that the activation and infiltration of lymph follicles in the thyroid during the course of autoimmune diseases lead to stimulation and activation of the surrounding mesenchyme producing tenascin as part of the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462272      PMCID: PMC500271          DOI: 10.1136/jcp.50.10.863

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

1.  The post-mortem incidence of focal thyroiditis.

Authors:  E D WILLIAMS; I DONIACH
Journal:  J Pathol Bacteriol       Date:  1962-01

2.  Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis.

Authors:  R Chiquet-Ehrismann; E J Mackie; C A Pearson; T Sakakura
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

3.  Tenascin, an extracellular matrix protein, exerts immunomodulatory activities.

Authors:  C R Rüegg; R Chiquet-Ehrismann; S S Alkan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

4.  Tenascin expression in human dermis is related to epidermal proliferation.

Authors:  J Schalkwijk; P M Steijlen; I M van Vlijmen-Willems; B Oosterling; E J Mackie; A A Verstraeten
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

5.  Tenascin in reactive lymph nodes and in malignant lymphomas.

Authors:  Y Soini; M Alavaikko; V P Lehto; I Virtanen
Journal:  Pathol Res Pract       Date:  1992-12       Impact factor: 3.250

6.  Altered content and distribution of tenascin in colitis, colon adenoma, and colorectal carcinoma.

Authors:  S E Riedl; A Faissner; P Schlag; A Von Herbay; K Koretz; P Möller
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

7.  Distribution of the extracellular matrix proteins tenascin, fibronectin, and vitronectin in fetal, infant, and adult human spleens.

Authors:  K A Liakka; H I Autio-Harmainen
Journal:  J Histochem Cytochem       Date:  1992-08       Impact factor: 2.479

8.  Focal lymphocytic thyroiditis in Southampton.

Authors:  J D Mitchell; N Kirkham; D Machin
Journal:  J Pathol       Date:  1984-12       Impact factor: 7.996

9.  Sequelae of concussion caused by minor head injuries.

Authors:  W H Rutherford
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

10.  Tenascin during gut development: appearance in the mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal interactions.

Authors:  E Aufderheide; P Ekblom
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.